Athira Pharma (ATHA)

• Market cap: $14.2M
• 1 day: -5.78%
• 5 days: -7.83%
• 1 month: -6.44%
• 3 months: 16.32%
• 6 months: 9.76%
• Year to date: -34.56%
• 1 year: -29.38%
• 5 years: -97.9%
• 10 years: -97.9%
• Sector: Healthcare
• Industry: Biotechnology

About: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

Employees: 26

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

6% more capital invested

Capital invested by funds: $5M [Q1] → $5.3M (+$299K) [Q2]

0.15% less ownership

Funds ownership: 44.99% [Q1] → 44.84% (-0.15%) [Q2]

7% less funds holding

Funds holding: 54 [Q1] → 50 (-4) [Q2]

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8